Background: Clopidogrel resistance testing is not routine prior to transcarotid artery revascularization (TCAR) and resistance rates are not well described in this setting despite frequent use of periprocedural clopidogrel. We compared 2 resistance testing modalities to determine the relationship between resistance and stent outcomes.
Methods: Consecutive patients undergoing TCAR at 3 institutions were retrospectively identified. Clopidogrel-resistance testing results and outcomes were described.
Results: A total of 210 patients underwent TCAR from 2018-2022. One hundred fifty four (73%) were on dual antiplatelet therapy (DAPT) for at least 7 days prior to TCAR. Twenty-nine patients were not on DAPT due to therapeutic anticoagulation and most (38/56, 68%) received a loading dose of a second antiplatelet the day of surgery. Twenty-five patients (11.9%) experienced stent thrombosis within 30 days. Patients not on DAPT for at least 7 days prior to surgery were more prone to stent thrombosis (16.7% vs. 10.4%, P = 0.164). More than half (133/210, 63%) of patients underwent resistance testing, 25 with thromboelastography with platelet mapping (TEG-PM), 103 with VerifyNow P2Y12 platelet reactivity assay, and 5 with both. Prevalence of Clopidogrel resistance among tested patients was 41%. In patients tested using both TEG-PM and VerifyNow, agreement was poor (Cohen's Kappa -0.05). Among patients with resistance, 12 (22%) experienced stent thrombosis. Comparatively, 8 (10%) patients without resistance developed thrombosis (P = 0.021). VerifyNow P2Y12 platelet reactivity assay correctly predicted Clopidogrel resistance more accurately than TEG-PM (70% vs. 40%, P = 0.025) and had sensitivity of 56% and specificity of 73% for stent thrombosis.
Conclusions: Our multi-institutional cohort confirms a high rate of Clopidogrel resistance in patients undergoing TCAR, with higher acute stent thrombosis rates noted in patients with resistance. VerifyNow P2Y12 platelet reactivity assays more reliably predict Clopidogrel resistance than TEG-PM.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.avsg.2024.09.031 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Selective Serotonin Reuptake Inhibitors and Bleeding Risk in the Geriatric Population.
Innov Clin Neurosci
December 2024
All authors are with Ocean University Medical Center in Brick, New Jersey.
Introduction: The demographics of the United States (US) are evolving as time progresses. The geriatric population is growing, with many elderly people dealing with mental health issues. Major depressive episodes affect 1 to 5 percent of those aged 65 years or older, which emphasizes the importance of addressing mental health concerns in this populace.
View Article and Find Full Text PDFProgress Analysis of Personalized Antiplatelet Therapy in Patients with Coronary Heart Disease Undergoing Interventional Therapy.
Rev Cardiovasc Med
December 2024
Department of Emergency, People's Hospital of Dali Bai Autonomous Prefecture, 671000 Dali, Yunnan, China.
Coronary atherosclerosis (or coronary heart disease [CHD]) is a common cardiovascular disease that seriously damages human health. Percutaneous coronary stent implantation represents the primary treatment option for severe CHD in clinical practice; meanwhile, dual antiplatelet therapy (DAPT) is widely used to reduce the risk of postoperative thrombosis. Although the mechanisms of action of the two most commonly used antiplatelet drugs, aspirin and clopidogrel, remain unclear, clinical studies have shown that some patients are susceptible to stent thrombosis-antiplatelet resistance (high on-treatment platelet reactivity [HTPR])-despite using these drugs.
View Article and Find Full Text PDFA review of clopidogrel resistance in lower extremity arterial disease.
JVS Vasc Insights
January 2024
Manchester Vascular Centre, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
Objective: Lower extremity arterial disease (LEAD) is a prevalent condition that produces a significant burden on health care systems. Patients with LEAD have an increased risk of major adverse cardiovascular events as well as major adverse limb events. Despite significant variation in guidance on antiplatelet therapy for LEAD worldwide, many governing bodies recommend clopidogrel as the preferred single anti-platelet agent.
View Article and Find Full Text PDFAnterior choroidal artery aneurysm case series: a clinical decision algorithm for endovascular and surgical treatment using a novel classification system.
Neurosurg Rev
December 2024
Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street, Boston, MA, 02215, USA.
Anterior choroidal artery (AChA) aneurysms represent 2-5% of intracranial aneurysms. The proximity of the origin of the AChA to the aneurysm neck poses a risk of thromboembolic complications following treatment. AChA occlusion can result in significant neurological deficits.
View Article and Find Full Text PDFIdentification of hsa_circ_0076957 and miR-4512-targeted COL19A1 as regulators in clopidogrel resistance among stable coronary heart disease patients through comprehensive circRNA and miRNA analysis.
Eur J Pharmacol
January 2025
Department of Traditional Chinese Internal Medicine, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China. Electronic address:
Background: Clopidogrel resistance (CR) increases the risk of atherothrombotic events. Emerging evidence suggests that circRNAs may influence pharmacodynamic responses to clopidogrel.
Methods: A total of 25 CR and 25 non-clopidogrel resistance (NCR) patients were enrolled.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!